Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

UroGen Pharma (URGN) Gains from Sales and Divestitures: 2017-2024

  • UroGen Pharma's Gains from Sales and Divestitures rose 31.14% to $385,065 in Q4 2024 from the same period last year, while for Dec 2024 it was $385,065, marking a year-over-year increase of 31.14%. This contributed to the annual value of $385,065 for FY2024, which is 31.14% up from last year.
  • UroGen Pharma's Gains from Sales and Divestitures amounted to $385,065 in Q4 2024, which was up 31.14% from $293,626 recorded in Q4 2023.
  • UroGen Pharma's Gains from Sales and Divestitures' 5-year high stood at $385,065 during Q4 2024, with a 5-year trough of $85,954 in Q4 2020.
  • Moreover, its 3-year median value for Gains from Sales and Divestitures was $374,293 (2022), whereas its average is $350,995.
  • Per our database at Business Quant, UroGen Pharma's Gains from Sales and Divestitures tumbled by 53.28% in 2020 and then spiked by 229.42% in 2021.
  • UroGen Pharma's Gains from Sales and Divestitures (Quarterly) stood at $85,954 in 2020, then skyrocketed by 229.42% to $283,147 in 2021, then spiked by 32.19% to $374,293 in 2022, then fell by 21.55% to $293,626 in 2023, then surged by 31.14% to $385,065 in 2024.
  • Its Gains from Sales and Divestitures stands at $385,065 for Q4 2024, versus $293,626 for Q4 2023 and $374,293 for Q4 2022.